NCT00632528 (KINOPA) is a Phase 3 clinical trial of MEOPA in Cerebral Palsy, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT00632528?

NCT00632528 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT00632528?

Interventions in NCT00632528: MEOPA, Medicinal air.

What condition does NCT00632528 study?

NCT00632528 studies Cerebral Palsy, Spastic Diplegia, Quadriplegia, Hemiplegia.

Is NCT00632528 still recruiting?

NCT00632528 is currently completed. Last updated 2 February 2023.

Last reviewed 2023-02-02 · How we verify

NCT00632528: KINOPA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Efficacy of "MEOPA" Used to Obtain Better ROM Immediately After Multilevel Surgery in Children With Spastic Diplegia, Quadriplegia or Hemiplegia.

Completed Phase 3 Last updated 2 February 2023

What this trial tests

Phase 3 trial testing MEOPA in Cerebral Palsy in 64 participants. Completed in 1 March 2011.

Timeline

1 March 2008

Primary endpoint
1 March 2011

1 March 2011

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	64
Start date	1 March 2008
Primary completion	1 March 2011
Estimated completion	1 March 2011
Sites	1 location across France

Drugs / interventions tested

MEOPA — full drug profile →
Medicinal air — full drug profile →

Conditions studied

Cerebral Palsy — all drugs for Cerebral Palsy →
Spastic Diplegia — all drugs for Spastic Diplegia →
Quadriplegia — all drugs for Quadriplegia →
Hemiplegia — all drugs for Hemiplegia →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 6 to 20, any sex, with Cerebral Palsy or Spastic Diplegia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Knee range of motion
Time frame: at 7 days

Sponsor's own description

Children with cerebral palsy commonly undergo "multilevel surgery", meaning several lower limb combined procedures performed during the same surgical intervention. The aim of this type of surgery is to correct all deformities together in order to restore near to normal anatomy and muscular function. It is very important to be able to obtain good range of motion after surgery, in order to consolidate surgical results. During the first days after the operation, children are sore and it may be difficult to realize adequate physical therapy. In order to palliate this situation, MEOPA gaz is used during REHAB sessions. Good results have been obtained so far but no study is available to demonstrate these results. The goal of our research is to prove that there is a benefit in using MEOPA postoperatively in these patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MEOPA

Trials testing the same drug.

NCT07118644 — Microbiote's Evolution After Use of Nitrous Oxide on Pediatric Patient Needing Airway Samples · Phase 3 · not yet recruiting
NCT03638921 — 35RC17_8826_NEPHROPAIN Phase APRES : Interest of the Equimolar Oxygen Nitride Mixture (MEOPA) in the Treatment of Pain i · Phase 2 · completed

Other recruiting trials for Cerebral Palsy

Currently open trials in the same condition.

NCT07524972 — Antenatal Magnesium Sulphate in High-Risk Preterm Patients · Phase 3 · recruiting
NCT07432789 — Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performa · NA · recruiting
NCT07466914 — Constipation in Children With Cerebral Palsy · active not recruiting
NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
NCT07342348 — Using Power Mobility Training to Promote Arm & Hand Function in Children With Cerebral Palsy · NA · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00632528 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 2 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00632528.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing